Top Markets
Coin of the day
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
Hisse Senetlerindeki Sıralama #41992
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
Hisse Fiyatı
$0.00001
Son senkronizasyon: 2026-08-07
Piyasa Değeri
$6.42K
Değişim (1 gün)
-90.00%
Değişim (1 yıl)
-90.00%
Ülke
US
Ticaret U.S. Stem Cell, Inc. (USRM)

Kategori

U.S. Stem Cell, Inc. (USRM) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $0.00 - 2026-08-01

Gün sonu en düşük fiyat: $4.76K - 2008-02-01
U.S. Stem Cell, Inc. için hisse fiyatı geçmişi: 2008 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) 0.00%
2025 -9.73%
2024 21.56%
2023 -98.44%
2022 -35.49%
2021 -4.78%
2020 68.67%
2019 -74.59%
2018 -52.30%
2017 1,490.45%
2016 -99.81%
2015 -91.16%
2014 44.54%
2013 -39.12%
2012 -69.35%
2011 -87.29%
2010 -49.66%
2009 -23.23%
2008 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.08K -7.16%
KR